The current results suggest TET-1 as responsible for the IL-1β-dependent tumor progression of the MCF-7 cell line, indicating its potential therapeutic treatment as a druggable target in breast cancer acting on progression and bone metastasis. Here, TET1 is linked to breast carcinoma.